Primary Objective: To assess the safety profile of autologous MitoCell administered to subjects with idiopathic Parkinson's disease (PD)
Secondary Objective: To explore the efficacy and safety of MitoCell given as the recommended dose by stereotactic intrastriatal implantation
Provision of signed and dated informed consent form
Aged 45 to 70 years old (inclusive) at Screening
Idiopathic Parkinson's disease patients who meet the diagnostic criteria of the "Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease"
With at least 5 years since the diagnosis of Parkinson's disease
Atypical or secondary Parkinsonism
With neurodegenerative disorders other than PD
Unable to receive MRI or PET scanning
With any concomitant disorder that would contraindicate coagulation, general anesthesia, or stereotactic neurosurgery